The mutational status of p53 can influence its recognition by human T-cells.

ABSTRACT: p53 was reported to be an attractive immunotherapy target because it is mutated in approximately half of human cancers, resulting in its inactivation and often accumulation in tumor cells. Peptides derived from p53 are presented by class I MHC molecules and may act as tumor-associated epitopes which could be targeted by p53-specific T cells. Interestingly, it was recently shown that there is a lack of significant correlation between p53 expression levels in tumors and their recognition by p53-TCR transduced T cells. To better understand the influence of the mutational status of p53 on its presentation by the MHC system and on T cell antitumor reactivity, we generated several mutant p53 constructs and expressed them in HLA-A2⁺/p53^- cells. Upon co-culture with p53-speci

SUBMITTER: Shamalov K 

PROVIDER: S-EPMC5414872 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature